Fulcrum Therapeutics rises on all-stock merger with Slate Medicines

Fulcrum Therapeutics

17/08/2026 12:25

**  Shares of drug developer Fulcrum Therapeutics FULC.O rise 4.8% to $3.92 premarket 
** Co agrees to merge with privately held Slate Medicines in an all-stock deal, with the combined company set to focus on Slate’s experimental migraine treatments
** Fulcrum shareholders are expected to own 5% of the combined company and receive an estimated $270 million cash dividend before the deal closes
** Combined company will focus on Slate’s lead migraine drug, SLTE-1009, with initial early-stage safety and drug-concentration data expected in mid-2027
** Deal is expected to close in Q4, subject to shareholder and regulatory approvals; combined company is expected to trade on Nasdaq under the ticker “SLTE”
** As of last close, FULC down 66.9% YTD 

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))